RISK  ||| S:0 E:5 ||| NN
FACTORS  ||| S:5 E:13 ||| NN
FOR  ||| S:13 E:17 ||| IN
INTRAVESICAL  ||| S:17 E:30 ||| NNP
RECURRENCE  ||| S:30 E:41 ||| NNP
AFTER  ||| S:41 E:47 ||| NNP
SURGICAL  ||| S:47 E:56 ||| NNP
MANAGEMENT  ||| S:56 E:67 ||| NNP
OF  ||| S:67 E:70 ||| IN
UROTHERIAL  ||| S:70 E:81 ||| NNP
CARCINOMA  ||| S:81 E:91 ||| NNP
OF  ||| S:91 E:94 ||| IN
THE  ||| S:94 E:98 ||| DT
UPPER  ||| S:98 E:104 ||| NNP
URINARY  ||| S:104 E:112 ||| NNP
TRACT  ||| S:112 E:118 ||| NNP
To  ||| S:118 E:121 ||| TO
identify  ||| S:121 E:130 ||| VB
risk  ||| S:130 E:135 ||| NN
factors  ||| S:135 E:143 ||| NNS
for  ||| S:143 E:147 ||| IN
developing  ||| S:147 E:158 ||| VBG
recurrent  ||| S:158 E:168 ||| JJ
bladder  ||| S:168 E:176 ||| NN
cancer  ||| S:176 E:183 ||| NN
in  ||| S:183 E:186 ||| IN
patients  ||| S:186 E:195 ||| NNS
who  ||| S:195 E:199 ||| WP
underwent  ||| S:199 E:209 ||| VBD
surgical  ||| S:209 E:218 ||| JJ
resection  ||| S:218 E:228 ||| NN
for  ||| S:228 E:232 ||| IN
urothelial  ||| S:232 E:243 ||| JJ
carcinoma  ||| S:243 E:253 ||| NN
of  ||| S:253 E:256 ||| IN
the  ||| S:256 E:260 ||| DT
upper  ||| S:260 E:266 ||| JJ
urinary  ||| S:266 E:274 ||| JJ
tract ||| S:274 E:279 ||| NN
.  ||| S:279 E:281 ||| .
We  ||| S:281 E:284 ||| PRP
retrospectively  ||| S:284 E:300 ||| VBP
analyzed  ||| S:300 E:309 ||| VBN
322  ||| S:309 E:313 ||| CD
patients  ||| S:313 E:322 ||| NNS
who  ||| S:322 E:326 ||| WP
underwent  ||| S:326 E:336 ||| VBD
surgical  ||| S:336 E:345 ||| JJ
resection  ||| S:345 E:355 ||| NN
for  ||| S:355 E:359 ||| IN
urothelial  ||| S:359 E:370 ||| JJ
carcinoma  ||| S:370 E:380 ||| NN
of  ||| S:380 E:383 ||| IN
the  ||| S:383 E:387 ||| DT
upper  ||| S:387 E:393 ||| JJ
urinary  ||| S:393 E:401 ||| JJ
tract  ||| S:401 E:407 ||| NN
at  ||| S:407 E:410 ||| IN
the  ||| S:410 E:414 ||| DT
Jikei  ||| S:414 E:420 ||| NNP
University  ||| S:420 E:431 ||| NNP
Hospital  ||| S:431 E:440 ||| NNP
and  ||| S:440 E:444 ||| CC
our  ||| S:444 E:448 ||| PRP$
affiliated  ||| S:448 E:459 ||| JJ
hospitals  ||| S:459 E:469 ||| NNS
between  ||| S:469 E:477 ||| IN
January  ||| S:477 E:485 ||| NNP
2005  ||| S:485 E:490 ||| CD
and  ||| S:490 E:494 ||| CC
July  ||| S:494 E:499 ||| NNP
2011 ||| S:499 E:503 ||| CD
.  ||| S:503 E:505 ||| .
Univariate  ||| S:505 E:516 ||| NNP
and  ||| S:516 E:520 ||| CC
multivariate  ||| S:520 E:533 ||| JJ
analyses  ||| S:533 E:542 ||| NNS
by  ||| S:542 E:545 ||| IN
using  ||| S:545 E:551 ||| VBG
the  ||| S:551 E:555 ||| DT
Cox  ||| S:555 E:559 ||| NNP
proportional  ||| S:559 E:572 ||| VBD
hazards  ||| S:572 E:580 ||| JJ
model  ||| S:580 E:586 ||| NN
were  ||| S:586 E:591 ||| VBD
performed  ||| S:591 E:601 ||| VBN
to  ||| S:601 E:604 ||| TO
determine  ||| S:604 E:614 ||| VB
the  ||| S:614 E:618 ||| DT
risk  ||| S:618 E:623 ||| NN
factors  ||| S:623 E:631 ||| NNS
for  ||| S:631 E:635 ||| IN
intravesical  ||| S:635 E:648 ||| JJ
recurrence  ||| S:648 E:659 ||| NN
after  ||| S:659 E:665 ||| IN
nephroureterectomy  ||| S:665 E:684 ||| NN
in  ||| S:684 E:687 ||| IN
these  ||| S:687 E:693 ||| DT
322  ||| S:693 E:697 ||| CD
patients ||| S:697 E:705 ||| NNS
.  ||| S:705 E:707 ||| .
Of  ||| S:707 E:710 ||| IN
the  ||| S:710 E:714 ||| DT
322  ||| S:714 E:718 ||| CD
patients ||| S:718 E:726 ||| NNS
,  ||| S:726 E:728 ||| ,
111  ||| S:728 E:732 ||| CD
patients  ||| S:732 E:741 ||| NNS
( ||| S:741 E:742 ||| -LRB-
34.5 ||| S:742 E:746 ||| CD
% ||| S:746 E:747 ||| NN
)  ||| S:747 E:749 ||| -RRB-
developed  ||| S:749 E:759 ||| VBD
recurrent  ||| S:759 E:769 ||| JJ
bladder  ||| S:769 E:777 ||| NN
cancer  ||| S:777 E:784 ||| NN
after  ||| S:784 E:790 ||| IN
a  ||| S:790 E:792 ||| DT
median  ||| S:792 E:799 ||| JJ
interval  ||| S:799 E:808 ||| NN
of  ||| S:808 E:811 ||| IN
8.0  ||| S:811 E:815 ||| CD
months ||| S:815 E:821 ||| NNS
.  ||| S:821 E:823 ||| .
On  ||| S:823 E:826 ||| IN
multivariate  ||| S:826 E:839 ||| JJ
analysis ||| S:839 E:847 ||| NN
,  ||| S:847 E:849 ||| ,
the  ||| S:849 E:853 ||| DT
presence  ||| S:853 E:862 ||| NN
of  ||| S:862 E:865 ||| IN
a  ||| S:865 E:867 ||| DT
superficial  ||| S:867 E:879 ||| JJ
tumor  ||| S:879 E:885 ||| NN
and  ||| S:885 E:889 ||| CC
the  ||| S:889 E:893 ||| DT
presence  ||| S:893 E:902 ||| NN
of  ||| S:902 E:905 ||| IN
a  ||| S:905 E:907 ||| DT
ureteral  ||| S:907 E:916 ||| JJ
tumor  ||| S:916 E:922 ||| NN
were  ||| S:922 E:927 ||| VBD
independent  ||| S:927 E:939 ||| JJ
predictors  ||| S:939 E:950 ||| NN
for  ||| S:950 E:954 ||| IN
intravesical  ||| S:954 E:967 ||| JJ
recurrence ||| S:967 E:977 ||| NN
.  ||| S:977 E:979 ||| .
The  ||| S:979 E:983 ||| DT
risk  ||| S:983 E:988 ||| NN
factors  ||| S:988 E:996 ||| NNS
for  ||| S:996 E:1000 ||| IN
developing  ||| S:1000 E:1011 ||| VBG
recurrent  ||| S:1011 E:1021 ||| JJ
bladder  ||| S:1021 E:1029 ||| NN
cancer  ||| S:1029 E:1036 ||| NN
were  ||| S:1036 E:1041 ||| VBD
the  ||| S:1041 E:1045 ||| DT
presence  ||| S:1045 E:1054 ||| NN
of  ||| S:1054 E:1057 ||| IN
a  ||| S:1057 E:1059 ||| DT
superficial  ||| S:1059 E:1071 ||| JJ
tumor  ||| S:1071 E:1077 ||| NN
and  ||| S:1077 E:1081 ||| CC
the  ||| S:1081 E:1085 ||| DT
presence  ||| S:1085 E:1094 ||| NN
of  ||| S:1094 E:1097 ||| IN
a  ||| S:1097 E:1099 ||| DT
ureteral  ||| S:1099 E:1108 ||| JJ
tumor ||| S:1108 E:1113 ||| NN
.  ||| S:1113 E:1115 ||| .
Further  ||| S:1115 E:1123 ||| JJ
investigation  ||| S:1123 E:1137 ||| NN
is  ||| S:1137 E:1140 ||| VBZ
required  ||| S:1140 E:1149 ||| VBN
to  ||| S:1149 E:1152 ||| TO
evaluate  ||| S:1152 E:1161 ||| VB
the  ||| S:1161 E:1165 ||| DT
efficacy  ||| S:1165 E:1174 ||| NN
of  ||| S:1174 E:1177 ||| IN
perioperative  ||| S:1177 E:1191 ||| JJ
intravesical  ||| S:1191 E:1204 ||| JJ
therapy  ||| S:1204 E:1212 ||| NN
for  ||| S:1212 E:1216 ||| IN
the  ||| S:1216 E:1220 ||| DT
prevention  ||| S:1220 E:1231 ||| NN
of  ||| S:1231 E:1234 ||| IN
intravesical  ||| S:1234 E:1247 ||| JJ
recurrence ||| S:1247 E:1257 ||| NN
.  ||| S:1257 E:1259 ||| .
